• All IHC stains will include a positive control tissue

• Androgen receptor (AR) positivity may be used to identify patients with metastatic breast cancer who may benefit from Bicalutamide therapy (prostate cancer drug)
• The majority of estrogen receptor positive breast cancers will also be AR positive; androgen receptors are most frequently seen in luminal A and B invasive breast cancers
• ARs are also seen in approximately one-third of basal-like cancers
• AR positive, estrogen receptor negative tumors are frequently apocrine type; these may be triple negative or HER2 positive tumors
• Request AR IHC evaluation on breast cases using image analysis
• AR is also useful in the diagnosis of salivary duct carcinomas. Approximately 90% of these tumors will be AR positive, and P63 negative

Submit a formalin-fixed, paraffin embedded tissue block

Formalin-fixed, paraffin embedded (FFPE) tissue block

Tissue section mounted on a charged, unstained slide

Ambient (preferred)

• Unlabeled/mislabeled
• Insufficient tissue
• Slides broken beyond repair

Immunohistochemical staining and microscopic examination

If requested, an interpretive report will be provided

Specifications

• This antibody is used to identify the androgen receptor in tumor cells

Staining patterns

• Strong nuclear staining

References

1. Niemeier LA, Dabbs DJ et al: Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol (2010) 23, 205–212.
2. Collins LC et al: Androgen Receptor Expression in Breast Cancer in Relation to Molecular Phenotype: Results from the Nurses’ Health Study. Mod Pathol. 2011 July; 24(7): 924–931. doi:10.1038/modpathol.2011.54
3. Robinson JLL et al: Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. The EMBO Journal (2011) 30, 3019–3027.